Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
14.34 USD -0.14% Intraday chart for Entrada Therapeutics, Inc. +8.97% -4.97%
May. 07 Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 13 Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Number of employees: 160

Sales per Business

USD in Million2022Weight2023Weight Delta
Endosomal Escape Vehicle Therapeutics
100.0 %
0 nan % 129 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 129 100.0 % -

Managers

Managers TitleAgeSince
Dipal Doshi CEO
 Chief Executive Officer 48 17-07-31
Kory Wentworth DFI
 Director of Finance/CFO 45 20-10-31
Nathan Dowden PSD
 President 54 19-11-03
Natarajan Sethuraman CTO
 Chief Tech/Sci/R&D Officer 62 17-08-31
Karla MacDonald PRN
 Corporate Officer/Principal - 21-05-31
Jared Cohen LAW
 General Counsel - 20-03-31
Kerry Robert HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Peter Kim BRD
 Director/Board Member 65 20-11-30
Mary Thistle BRD
 Director/Board Member 64 21-05-03
Gina Chapman BRD
 Director/Board Member 57 23-08-31
Dipal Doshi CEO
 Chief Executive Officer 48 17-07-31
Kush Parmar CHM
 Chairman 42 16-09-30
Bernhardt Zeiher BRD
 Director/Board Member 60 23-04-03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,783,451 27,802,706 ( 82.30 %) 0 82.30 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
14.45 %
4,865,819 14.45 % 60 M $
MPM BioImpact, Inc
13.14 %
4,425,784 13.14 % 55 M $
5AM Venture Management LLC
13.09 %
4,408,379 13.09 % 54 M $
T. Rowe Price International Ltd.
8.937 %
3,009,673 8.937 % 37 M $
ROCHE HOLDING AG
8.148 %
2,744,120 8.148 % 34 M $
MERCK & CO., INC.
5.166 %
1,739,768 5.166 % 22 M $
BlackRock Advisors LLC
4.162 %
1,401,779 4.162 % 17 M $
Redmile Group LLC
3.812 %
1,283,735 3.812 % 16 M $
Vanguard Fiduciary Trust Co.
3.204 %
1,078,908 3.204 % 13 M $
Wellington Management Co. LLP
3.111 %
1,047,780 3.111 % 13 M $

Company contact information

Entrada Therapeutics, Inc.

One Design Center Place

02210, Boston

+

http://www.entradatx.com
address Entrada Therapeutics, Inc.(TRDA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Entrada Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.34 USD
Average target price
21 USD
Spread / Average Target
+46.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENTRADA THERAPEUTICS, INC. Stock Entrada Therapeutics, Inc.
-4.97% 455M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. Company Entrada Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW